| 3.17 -0.25 (-7.31%) | 09-01 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.74  |
1-year : | 0.92 |
| Resists | First : | 0.63 |
Second : | 0.79 |
| Pivot price | 0.56  |
|||
| Supports | First : | 0.38 |
Second : | 0.32 |
| MAs | MA(5) : | 0.53 |
MA(20) : | 0.59 |
| MA(100) : | 0.38 |
MA(250) : | 1.04 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28 |
D(3) : | 28.1 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 3.33 | Low : | 0.12 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BCLI ] has closed above bottom band by 33.6%. Bollinger Bands are 12.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.56 - 0.56 | 0.56 - 0.56 |
| Low: | 0.51 - 0.52 | 0.52 - 0.52 |
| Close: | 0.53 - 0.53 | 0.53 - 0.54 |
Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
Tue, 07 Sep 2021
Statera BioPharma: The Ticker Formerly Known as CBLI - Yahoo Finance
Tue, 31 Aug 2021
Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc." - PR Newswire
Wed, 28 Jul 2021
Cytocom Inc. Announces Completed Merger with Cleveland BioLabs - PR Newswire
Sat, 19 Dec 2020
Penny Stocks To Buy Or Avoid Next Week? 1 Has A 100% Price Target - Penny Stocks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 68 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 12.8 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 1,340 (K) |
| Shares Short P.Month | 1,070 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -211.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.34 |
| PEG Ratio | 0 |
| Price to Book value | -6.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|